Global Gastric Cancer Market, By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), Stages (Stage I, Stage II, Stage III, Stage IV, Others), Diagnosis (Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others), Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Gastric Cancer Market Analysis and Size
The global gastric cancer market is expected to witness significant growth during the forecast period. Rising cases of gastrointestinal reflux disease boost the gastric cancer market. Rising adoption of unhealthy lifestyle such as obesity and smoking, genetic modification in genes and family history with cancer also increase the gastric cancer market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global gastric cancer market in the forecast period 2022-2029. The expected CAGR of global gastric cancer market is tend to be around 16% in the mentioned forecast period. The market was valued at USD 4 billion in 2021, and it would grow upto USD 13.11 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Gastric cancer is the condition noted by the abnormal growth of cancerous cells within the stomach lining. This type of cancer is usually difficult to diagnose in the early stage till the time it spreads to other parts of the body. Symptoms of include unexplained, persistent nausea, fatigue, feeling bloated after eating, stomach pain, persistent vomiting and unintentional weight loss. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Gastric Cancer Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), Stages (Stage I, Stage II, Stage III, Stage IV, Others), Diagnosis (Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others), Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Eisai Co., Ltd (Japan), Provell Pharmaceuticals, LLC (U.S.), Piramal Critical Care (India) |
|
Market Opportunities |
|
Global Gastric Cancer Market Dynamics
Drivers
- Quick Launches and Approvals From Authorities
Fast approvals from the regulatory authorities associated with gastric cancer may bring immense growth prospects for the gastric cancer market. R&D activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. The team performed targeted therapy which can efficiently reduce tumor growth. These developments may bring remarkable growth prospects for the gastric cancer market. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Gastric Cancer Cases
According to National Cancer Institute (NCI) in 2017, there was an estimated approximately 28,000 new cases of stomach cancer and 1.7% of new cancer cases in the U.S.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for treating gastric cancer are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the treatment methods for this disease could curb the growth of the global gastric cancer market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global gastric cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gastric cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Gastric Cancer Market Scope
The global gastric cancer market is segmented on the basis of stages, type, stages, treatment, diagnosis, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Adenocarcinoma
- Lymphoma
- Gastrointestinal Stromal Tumor
- Carcinoid Tumor
- Others
Stages
- Stage I
- Stage II
- Stage III
- Stage IV
- Others
Diagnosis
- Endoscopy
- Biopsy
- Imaging Tests
- Exploratory Surgery
- Other
Treatment
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Palliative Care
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Gastric Cancer Market Regional Analysis/Insights
The global gastric cancer market is analysed and market size insights and trends are provided by stages, type, treatment, diagnosis, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global gastric cancer market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to increased government awareness programs and number of generic drugs.
North America dominates the market due to the presence of key manufacture of the product, high research and development, healthcare expenditure, and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Gastric Cancer Market Share Analysis
The global gastric cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global gastric cancer market.
Key players operating in the global gastric cancer market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Eisai Co., Ltd (Japan)
- Provell Pharmaceuticals, LLC (U.S.)
- Piramal Critical Care (India)
SKU-
